BioTrinity is the premier European Biopartnering and Investment Conference, partnering R&D companies with big pharma and more biomedical investors than any other European partnering conference. Check out who else is coming, we expect about 850 delegates including nearly 80 investment firms, hear what delegates say about BioTrinity, the expert discussion panels, and which 90 companies will be presenting in the showcase. Don't miss out:
Meet the key licensing contacts from big pharma including AbbVie, Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GE, GSK, Ipsen, J&J, Janssen R&D, Linde Healthcare, MSD, Novartis, Novo Nordisk, Shire, Pfizer, Takeda, Teijin, UCB as well as Vertex, Genus, EUSA, Nordic Pharma, Mercury and other senior BD&L execs
Meet 100 delegates from active VC and Corporate Venture firms including MedImmune Ventures, SR One, Shire Strategic Investment, AbbVie Biotech Ventures, Mitsui & Co., MPHVM, Norgine Investment Fund, Novartis Venture Fund, Takeda Ventures, Boehringer Ingelheim Ventures, Inventages, Amorepacific Ventures as well as Syncona, Index, Sofinnova and many international VCs
Meet a hand-picked crop of early-stage companies you haven't seen elsewhere
Meet the senior execs who can complete the value chain for your business
...Deploying EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering:
![]()
|
You need to upgrade your Flash Player
|
The "Event of the Year" - BioTrinity 2013:
Exciting Social Programme:
Check out the glowing testimonials we received for BioTrinity, or view the photos from the Gallery |
|